Tag: Claudin 18.2 Targeted Therapy

Home / Claudin 18.2 Targeted Therapy

Categories

Zolbetuximab-clzb with chemotherapy is approved by the USFDA for gastric or gastroesophageal junction adenocarcinoma

 On October 18, 2024, the Food and Drug Administration sanctioned zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.), a claudin 18.2 (CLDN18.2)-targeted cytolytic antibody, in conjunction with fluor...
claudin-18-2-targeted-therapy

Scan the code